AI Terminal
Valneva SE
AGM Information • May 31, 2023
1739_iss_2023-05-31_c00eafe0-14a4-4487-9f27-3d60ead0d24e.pdf
AGM Information
Open in ViewerOpens in native device viewer
VALNEVA SE Campus Bio-Ouest | 6, Rue Alain Bombard 44800 Saint-Herblain, France
Valneva Announces the Availability of Documentation for its Shareholder Meeting
Saint-Herblain (France), May 31, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the availability of documentation for its Combined General Meeting to be held on June 21, 2023 at 2 p.m. CEST, at the hotel InterContinental Lyon – Hotel Dieu, 20 Quai Jules Courmont, 69002 Lyon (France).
The preliminary Notice of Meeting, containing the agenda, the draft resolutions and instructions for participation and voting, was published in the French Bulletin des Annonces Légales Obligatoires (BALO) on May 15, 2023.
Documents and information relating to the Meeting are available on Valneva's website (www.valneva.com) in the "Investors/General Meetings" section. Shareholders can also obtain the Combined General Meeting documents upon request to the Company by sending an email to the following address: [email protected].
The Company also recommends that shareholders regularly consult the Combined General Meeting section of its website, www.valneva.com.
Contact Details, Legal Department
Valneva SE Service Assemblée Générale 6 rue Alain Bombard, 44800 Saint-Herblain (France) [email protected]
Media & Investor Contacts
Laëtitia Bachelot-Fontaine VP Global Communications & European Investor Relations M +33 (0)6 4516 7099 [email protected]
Joshua Drumm, Ph.D. VP Global Investor Relations M +001 917 815 4520 [email protected]
About Valneva SE
We are a specialty vaccine company focused on the development, manufacturing and commercialization of prophylactic vaccines for infectious diseases. We take a highly specialized and targeted approach to vaccine development by focusing on vaccine solutions addressing unmet medical needs to ensure we can make a difference to peoples' lives. We apply our deep understanding of vaccine science, including our expertise across multiple vaccine modalities, and our established vaccine development capabilities, to develop vaccines against diseases which are not yet vaccinepreventable, or for which there are limited effective treatment options. Today, we are leveraging our expertise and capabilities to rapidly advance a broad range of vaccines into and through the clinic, including candidates against the chikungunya virus and Lyme disease.